Comparison of Clinical Outcomes Between Ticagrelor and Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction - Results From the Korea Acute Myocardial Infarction Registry-National Institutes of Health -
- Authors
- Kim, Min Chul; Jeong, Myung Ho; Sim, Doo Sun; Hong, Young Joon; Kim, Ju Han; Ahn, Youngkeun; Ahn, Tae Hoon; Seung, Ki Bae; Choi, Dong-Ju; Kim, Hyo-Soo; Gwon, Hyeon Cheol; Seong, In Whan; Hwang, Kyoung-Kook; Chae, Shung Chull; Hur, Seung Ho; Cha, Kwang Soo; Oh, Seok Kyu; Chae, Jei Keon
- Issue Date
- Jul-2018
- Publisher
- JAPANESE CIRCULATION SOC
- Keywords
- Percutaneous coronary intervention; Prasugrel; ST elevation myocardial infarction; Ticagrelor
- Citation
- CIRCULATION JOURNAL, v.82, no.7, pp.1866 - +
- Journal Title
- CIRCULATION JOURNAL
- Volume
- 82
- Number
- 7
- Start Page
- 1866
- End Page
- +
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3631
- DOI
- 10.1253/circj.CJ-18-0112
- ISSN
- 1346-9843
- Abstract
- Background: There is little information regarding comparison of ticagrelor and prasugrel in patients with ST-segment elevation myocardial infarction (STEMI). We sought to compare clinical outcomes between ticagrelor and prasugrel in STEMI. Methods and Results: A total of 1,440 patients with STEMI who underwent successful primary percutaneous coronary intervention were analyzed; the data were obtained from the Korea Acute Myocardial Infarction Registry-National Institutes of Health. Of the patients, 963 received ticagrelor, and 477 received prasugrel. The primary study endpoint was 12-month major adverse cardiac events (MACE), including cardiac death, myocardial infarction (MI), and target vessel revascularization (TVR). MACE occurred in 91 patients (6.3%) over the 1-year follow-up, and there were no differences in the incidence of MACE (hazard ratio [HR] 1.20, 95% confidence interval [CI] 0.76-1.91, P=0.438) between the 2 groups. Analysis by propensity score matching (429 pairs) did not significantly affect the results. The incidence of in-hospital major bleeding events was still comparable between the 2 groups (2.4% vs. 2.5%, odds ratio 0.75, 95% CI 0.30-1.86, P=0.532), and there was no significant difference in the incidence of MACE (5.4% vs. 5.8%, HR 0.98, 95% CI 0.56-1.74, P=0.951) after matching. Conclusions: Ticagrelor and prasugrel showed similar efficacy and safety profiles for treating STEMI in this Korean multicenter registry.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3631)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.